SCHEMBL1749456

SCHEMBL1749456

O=c1nc2nc[nH]cc-2[nH]1

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162436 0.65 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2210364 0.61 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL26611966 0.55 L3MBTL1 (0.31)
Fluoxidine SCHEMBL11601291 0.55
SCHEMBL12635219 0.55
SCHEMBL15109875 0.54 QPCT (0.33)
Purine SCHEMBL28150963 0.54
SCHEMBL916879 0.52 POLB (0.44) ALDH1A1HPGD
SCHEMBL7561735 0.52
SCHEMBL12320643 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968556-B2 Heteroaryl compounds, compositions thereof, and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC (US) 2011-06-28 US claimed
US-20140301947-A1 METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO IMPERIAL INNOVATIONS LIMITED (GB) 2014-10-09 US disclosed
EP-2718464-A1 METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO Imperial Innovations Limited (GB) 2014-04-16 EP disclosed
US-8501735-B2 N-containing heteroaryl derivatives as JAK3 kinase inhibitors PALAU PHARMA, S.A. (ES) 2013-08-06 US disclosed
US-20130131038-A9 N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS VECTURA LIMITED (GB) 2013-05-23 US disclosed
WO-2012168697-A1 METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO IMPERIAL INNOVATIONS LIMITED (GB) 2012-12-13 WO disclosed
US-20120245140-A1 N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS ALMANSA ROSALES CARMEN (ES) 2012-09-27 US disclosed
WO-2007103162-A2 STRUCTURE BASED DRUG DESIGN OF STEROIDOGENESIS INHIBITORS SAMARITAN PHARMACEUTICALS, INC. (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140301947-A1 METHODS TO PREDICT BINDING AFFINITY OF TSPO IMAGING AGENTS TO TSPO TSPO, GPR174, TSG101 KDM4E 4857/4885ALDH1A1 2681/4885HPGD 2051/4885
US-20120245140-A1 N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS JAK3, JAK2, JAK1 KDM4E 2056/4885ALDH1A1 3830/4885HPGD 2242/4885
US-20130131038-A9 N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS JAK3, JAK2, JAK1 KDM4E 2056/4885ALDH1A1 3830/4885HPGD 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.